Dauvergne Jerome E, Boissier Elodie, Rozec Bertrand, Lakhal Karim, Muller Damien
Nantes Université, CHU Nantes, INSERM, Service d'anesthésie-réanimation, Hôpital Laënnec, CIC 1413, Nantes, F-44000, France.
Nantes Université, CHU Nantes, CNRS, INSERM, l'Institut du Thorax, Nantes, F-44000, France.
J Clin Monit Comput. 2025 Jun;39(3):607-612. doi: 10.1007/s10877-024-01252-0. Epub 2024 Dec 12.
After blood sampling from an arterial catheter, the reinjection of the clearing fluid (a mixture of saline solution and blood) is proposed to limit blood loss. However, reinjecting clots may cause embolic complications. The primary objective was to assess fibrinogen consumption in the clearing fluid as an indicator of clot formation over time. Additionally, we searched for macroscopic clots, evaluated changes in prothrombin time, factors II and V. In this prospective observational pilot study, we enrolled adult patients in an intensive care unit with a radial artery catheter who required measurements of hemostasis parameters. We used a locally developed closed blood sampling system. Hemostasis parameters were measured in patients' pure blood (reference) and in the clearing fluid, at 2, 3, and 5 min after the complete filling of the reservoir. Thirty patients were included and 120 samples were analyzed. Fibrinogen levels decreased over time: median [interquartile range (IQR)] of 4.3 [IQR:3.1;5.9] as reference level, 3.6 [IQR:2.7;4.7] at 2 min (p < 0.001), 3.4 [IQR:2.1;4.3] at 3 min (p < 0.001) and 3.0 [IQR:1.7;4.1] g/L at 5 min (p < 0.001). No clot was macroscopically detected in any samples. An antiplatelet agent was administered in 11 (37%) patients. Unfractionated heparin anti-Xa activity was higher than 0.10 UI/ml in 17 (57%). Although no macroscopic clots were observed in the clearing fluid, its coagulation factors decreased over the 5 min following reservoir filling, indicating potential initiation of clot formation. Our findings stress the need for further studies assessing the safety of reinjecting clearing fluid as part of patient blood management.
在从动脉导管采集血液样本后,建议回注清除液(盐水溶液和血液的混合物)以限制失血。然而,回注凝块可能会导致栓塞并发症。主要目的是评估清除液中纤维蛋白原的消耗情况,以此作为随时间推移凝块形成的指标。此外,我们还查找了肉眼可见的凝块,评估了凝血酶原时间、凝血因子II和V的变化。在这项前瞻性观察性试点研究中,我们纳入了重症监护病房中需要测量止血参数且带有桡动脉导管的成年患者。我们使用了本地研发的封闭式血液采样系统。在储液器完全充满后的2分钟、3分钟和5分钟,对患者的纯血(对照)和清除液中的止血参数进行了测量。共纳入30例患者,分析了120份样本。纤维蛋白原水平随时间下降:作为对照水平,中位数[四分位间距(IQR)]为4.3[IQR:3.1;5.9]g/L,2分钟时为3.6[IQR:2.7;4.7]g/L(p<0.001),3分钟时为3.4[IQR:2.1;4.3]g/L(p<0.001),5分钟时为3.0[IQR:1.7;4.1]g/L(p<0.001)。在任何样本中均未肉眼检测到凝块。11例(37%)患者使用了抗血小板药物。17例(57%)患者的普通肝素抗Xa活性高于0.10 UI/ml。尽管在清除液中未观察到肉眼可见的凝块,但其凝血因子在储液器充满后的5分钟内有所下降,表明可能开始形成凝块。我们的研究结果强调需要进一步开展研究,以评估作为患者血液管理一部分回注清除液的安全性。